Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Progettazione e valutazione di un programma di riabilitazione cardiaca (CARE) riservato alle donne (CARE)

6 novembre 2026 aggiornato da: Melvyn Rubenfire, University of Michigan

Progettare e valutare un programma di riabilitazione cardiaca per sole donne

The purpose of this randomized controlled study is to investigate the effect(s) of a pilot women-only cardiac rehabilitation (CR) program. The study team will be testing the effectiveness, compliance and enjoyment of this women's only cardiac rehabilitation (CR) program by comparing outcomes to those randomized to receive Michigan Medicine's current CR program (standard care), which includes people of all genders.

Study hypotheses:

  • Women randomized to women-specific CR programming will have superior attendance and completion rates compared to women attending mixed-sex CR programming.
  • Women randomized to women-specific CR programming will experience greater improvement in clinical outcomes in comparison to those in mixed-sex CR programming.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This registration was updated on 11/24/2025 due to amendments that were approved at the IRBMED.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan
        • Contatto:
        • Investigatore principale:
          • Melvyn Rubenfire, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 40 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability to participate in study procedures for the duration of the study
  • Identify as a female
  • Be between the ages of 40-80 years, inclusive
  • Documented diagnosis of CR indications of stable and/or refractory angina pectoris (with or without coronary obstructive disease), acute myocardial infarction (MI) within the preceding 12 months (including MINOCA), percutaneous coronary interventions (PCI), surgical and transvalvular aortic valve replacement, spontaneous coronary artery dissection (SCAD), post-aortic surgery with or without aortic valve, coronary artery bypass grafting (CABG) and mitral valve replacement or repair with or without CABG
  • Referred to outpatient CR at the University of Michigan, Domino's Farms or Brighton Center for Specialty Care Cardiac Rehabilitation site based on Michigan Medicine's Division of Cardiovascular Medicine Policy and Procedure.

Exclusion Criteria:

  • Not being "cleared" for CR based on Michigan Medicine's Division of Cardiovascular Medicine Policy and Procedures
  • Prior participation in CR
  • Inability to understand spoken and written English, either due to language barrier or cognitive limitation for any reason, including deaf or blind
  • Frailty, fall risk, or muscle, joint or back pain as defined as the inability to perform activities of daily living without limitations and engage in mild physical activity (i.e. unable to walk up 1 flight of stairs unaided)
  • Any of the following as the indication for CR: aortic repair or replacement for aortic dissection, untreated or greater than New York Heart Association (NYHA) class II congestive heart failure, cardiac transplant candidate or recipient, tricuspid or pulmonic valve repair or replacement
  • Life threatening ventricular arrythmias without an implanted defibrillator; very frequent premature ventricular contraction or premature atrial contractions symptomatic or not; poorly controlled atrial fibrillation
  • Associated more than mild valvular heart disease, untreated congestive heart failure; unstable angina or heart pain with minimal activity; angina or congestive heart failure limiting ability to climb one flight of stairs without help (NHYA Functional Classification >2)
  • Severe pulmonary hypertension (right heart systolic pressure greater than 60 millimeters of mercury); clot in the heart; treated venous thrombosis with or without pulmonary embolism in past 6 months; more than mild dyspnea related to chronic lung disease or asthma
  • Chronic kidney disease (creatinine >2 milligrams per deciliter (mg/dl)); symptomatic active liver disease (infectious or inflammatory), symptomatic chronic liver disease (except for nonalcoholic fatty liver disease), kidney dialysis or kidney transplant recipient, active or chronic renal disease (rise by 0.5mg/dL in past 3 months or chronic elevated serum creatinine 2.0 milligrams per milliliter (mg/mL) or greater.
  • Poorly controlled diabetes defined as uninterrupted HbA1c >8.0% for ≥1 year despite standard care, baseline HbA1c prior to CR > 8.5%.
  • Immunosuppressive drug requirement, acute anemia, chronic anemia with Hemoglobin < 10mg/mL
  • Limiting chronic muscle, joint, or back pain; identified as fall risk from poor balance or neurologic syndromes; frailty defined as the inability to perform activities of daily living in older adults that carries an increased risk for poor health outcomes including falls, incident disability, hospitalization, and mortality
  • Untreated or active substance abuse/addiction including alcohol and drugs; depression (defined as a score ≥ 15 or depression positive answer to #8 or #9 on Patient Health Questionnaire-9) unless deemed acceptable by mental health care provider; severe anxiety
  • Severe obesity (Body mass index ≥ 40 kilograms/meters squared), history of bariatric surgery within previous 3 years and >5% body weight loss over preceding 12 months; chronic venous insufficiency with cellulitis or > 1+ edema unless controlled with support hose.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Programma di riabilitazione cardiaca per sole donne

This is a 12-week program and will include 36 sessions 3 times a week. This group will also have Women-Only Education sessions. Participants will also have a 24-week follow-up visit from the time of entry.

Women-specific education content will be provided monthly in addition to the standard weekly "mini-teaches." This education content will be developed and delivered by experience health care professionals that are experts in women's health.

Comparatore attivo: Programma di riabilitazione Standard of Care (sesso misto).

This is a 12-week program and will include up to 36 sessions 3 times a week. Participants will also have a 24-week follow-up visit from the time of entry. Exercise classes are medically supervised, and each program is individualized based upon medical history, cardiac risk factors, goals, and initial fitness level. Educational programs are arranged in a continuing series, with sessions taught by experts in nutrition therapy, stress reduction therapy, and exercise.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cardiac Rehabilitation (CR) attendance rate
Lasso di tempo: 12 weeks (post CR)

CR completion rate defined as number of patients that "graduated" or completed CR programming versus the number of patients that started CR programming [i.e. attended 75% or more of the prescribed sessions (≥27 out of 36)], expressed as a percentage of participants per arm.

12 weeks (post CR)
Cardiac Rehabilitation (CR) attendance rate - percentage
Lasso di tempo: 12 weeks (post CR)

Number of CR sessions attended out of number of CR sessions prescribed, expressed as a percentage

12 weeks (post CR)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Optimal blood pressure (BP) control
Lasso di tempo: 12 weeks (post CR)

Percentage of patients that have optimal BP control at program discharge, defined as systolic blood pressure (SBP) less than 130 mmHg and diastolic blood pressure (DBP) less than 80 Millimeters of mercury (mmHg).

12 weeks (post CR)
Change in resting systolic blood pressure (SBP)
Lasso di tempo: Baseline, 12 weeks (post CR)

Change in resting SBP from baseline to CR completion, measured using an automated blood pressure monitor and expressed in mmHg.

Baseline, 12 weeks (post CR)
Change in resting diastolic blood pressure (DBP)
Lasso di tempo: Baseline, 12 weeks (post CR)

Change in resting DBP from baseline to CR completion, measured using an automated blood pressure monitor and expressed in mmHg.

Baseline, 12 weeks (post CR)
Improvement in depression based on the Patient Health Questionnaire (PHQ)-9
Lasso di tempo: Baseline to 12 weeks (post CR)

Percentage (%) of patients with a positive depressive screen at CR entrance that experience a decrease in depressive symptoms (reduction in one or more levels of severity) as measured by changes in the Patient Health Questionnaire (PHQ)-9 score from baseline to completion of CR.

The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression.

Baseline to 12 weeks (post CR)
Change in Patient Health Questionnaire (PHQ)-9 score
Lasso di tempo: Baseline to 12 weeks (post CR)

A change in PHQ-9 scores will be measured during the first 12 weeks of the study. The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression.

Baseline to 12 weeks (post CR)
Change in Patient Health Questionnaire (PHQ)-9 score
Lasso di tempo: 12 weeks (post CR), 24 weeks

The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression. A change in PHQ-9 scores will be measured during the first 12 weeks of the study and will be repeated 12 weeks following program completion.

12 weeks (post CR), 24 weeks
Improvement in functional capacity measured by the six-minute walk test
Lasso di tempo: Baseline, up to 12 weeks (post CR)

Percentage of patients that achieve an increase in distance walked, in meters, by at least 10%, after participation in CR as measured by the 6-minute walk test (6MWT).

Baseline, up to 12 weeks (post CR)
Change in 6-minute walk test distance
Lasso di tempo: Baseline, 12 weeks (post CR)

The distance walked in six minutes on a standard course will be measured in meters at baseline and CR Exit

Baseline, 12 weeks (post CR)
Improvement in functional capacity Metabolic Equivalents (METs)
Lasso di tempo: Baseline, 12 weeks (post CR)

Percentage of patients that display an overall mean increase in estimated METs (0.93 METs, 12.4%): with greatest increase occurring in "low" fitness patients < 5 METs (1.3 METs, 35% increase), followed by "moderate" fitness 5-8 METs (1.03 METs, 16% increase), and "high" fitness > 8 METs (0.77 METs, 8% increase)2,3 after participation in CR as measured by estimated exercise session peak METs.

Baseline, 12 weeks (post CR)
Change in estimated exercise session peak METs
Lasso di tempo: Baseline, up to 12 weeks (post CR)

The difference in estimated peak METs between baseline (defined as the third session to account for learning effect) and program completion.

Baseline, up to 12 weeks (post CR)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Melvyn Rubenfire, MD, University of Michigan

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 maggio 2025

Completamento primario (Stimato)

1 agosto 2027

Completamento dello studio (Stimato)

1 agosto 2027

Date di iscrizione allo studio

Primo inviato

16 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

16 gennaio 2025

Primo Inserito (Effettivo)

20 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • HUM00252649

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .